مقارنة بين الإيفيرميكتين الفموي والبيرميثرين الموضعي في معالجة الجرب

Authors

  • محمد اسماعيل
  • عبد الله الخير
  • رشا العاصي

Abstract

شملت هذه الدراسة (105) مرضى مصابين بالجرب من مراجعي العيادة الخارجية في قسم الأمراض الجلدية في مستشفى الأسد الجامعي باللاذقية خلال الفترة الممتدة بين تموز2008 وتموز 2009 . وقد تم استبعاد الأطفال دون سن الخامسة, فضلاً عن الحوامل و المرضعات و المصابين بأمراض كلوية أو كبدية أو قلبية أو عصبية, فضلاً عن المرضى الذين استخدموا مضاد للجرب قبل أسبوع من الدراسة .

وتم تقسيم المرضى عشوائياً إلى مجموعتين: ضمت المجموعة الأولى 50 مريضا" عولجوا بالإيفيرميكتين الفموي إذ تم إعطاء الدواء كمضغوطة تحوي 6 ملغ وكجرعة كلية ( 200 مكغ \ كغم )حسب وزن جسم المريض. وضمت المجموعة الثانية 55 مريضا" عولجوا  موضعيا" بدهون البيرميثرين 5% .

كما تم تصنيف شدة المرض حسب الاندفاعات إلى: خفيف (10 اندفاعات أو أقل ), متوسط (من 11-49 اندفاعاً) , شديد ( 50 اندفاعاً أو أكثر ) .

إن هدف هذه الدراسة تقدير فعالية الايفيرميكتين و تحديد درجة أمانه عند استخدامه في علاج الجرب الإنساني والمقارنة بين فعالية الإيفيرمكتين بجرعة فموية 200 مكغ/كغم والبيرميثرين 5%الموضعي .

This study included 105 scabietic patients attending the outpatient clinic of Al-assad University Hospital in Lattakia from July 2008 to July 2009. Children  aged less than 5 years, patients who had received any antiscabietic treatment a week before this study was conducted, pregnant and lactating women, and patients with serious central nervous system, hepatic, cardiac, or renal diseases were excluded from this study. Patients chosen were divided into two groups. The first included 50 patients and was treated by oral ivermectin which was administered as scored 6-mg tablets, and the dose was designed to provide 200μg/kg. The second included 55 patients and was treated by topical permethrin 5%. The severity of disease was considered mild (10 or fewer lesions), moderate (11-49 lesions), or severe (50 lesions or more). The aim of the study was to determine  the efficacy and safety of ivermectin  and to compare the efficacy of a single oral dose of 200 μg/kg of body weight of ivermectin with a topical lotion of 5% permethrin in the treatment of human scabies.

Downloads

Published

2019-01-20

How to Cite

1.
اسماعيل م, الخير عا, العاصي ر. مقارنة بين الإيفيرميكتين الفموي والبيرميثرين الموضعي في معالجة الجرب. Tuj-hlth [Internet]. 2019Jan.20 [cited 2024Nov.24];32(3). Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/6719

Issue

Vol. 32 No. 3 (2010): العلوم الصحية

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.